Amphetamine Response and Relapse Risk After Depot Neuroleptic Discontinuation

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1985 Jan 1

PMID 2860683

Citations 9

Authors

B Angrist

E Peselow

M Rubinstein

A WOLKIN

J Rotrosen

Affiliations

Soon will be listed here.

Abstract

Twenty-five schizophrenic outpatient subjects in a depot neuroleptic discontinuation study received an amphetamine challenge approximately 6 weeks after their last dose. Only five of these showed greater than three-point increases in positive symptoms on the BPRS, and all five relapsed within 30 days of the challenge. The 20 with less than three-point increases in positive symptoms showed extremely variable stability, relapsing from 20- greater than 600 days after the challenge. Thus, increase in positive symptoms after amphetamine may identify a group at risk for rapid relapse after neuroleptic discontinuation, but lack of such a response gives little prognostic information.

Citing Articles

The Black Book of Psychotropic Dosing and Monitoring.

Schatzberg A, Charles D Psychopharmacol Bull. 2018; 48(1):64-153.

PMID: 29382960 PMC: 5765435.

New Concepts in Dopamine D Receptor Biased Signaling and Implications for Schizophrenia Therapy.

Urs N, Peterson S, Caron M Biol Psychiatry. 2016; 81(1):78-85.

PMID: 27832841 PMC: 5702557. DOI: 10.1016/j.biopsych.2016.10.011.

Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex.

Clinton S, Sucharski I, FINLAY J Psychopharmacology (Berl). 2005; 183(4):404-12.

PMID: 16307295 DOI: 10.1007/s00213-005-0221-2.

Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition.

Tenn C, Kapur S, Fletcher P Psychopharmacology (Berl). 2005; 180(2):366-76.

PMID: 15856186 DOI: 10.1007/s00213-005-2253-z.

Levodopa reverses gait asymmetries related to anhedonia and magical ideation.

Mohr C, Landis T, Bracha H, Fathi M, Brugger P Eur Arch Psychiatry Clin Neurosci. 2004; 255(1):33-9.

PMID: 15538593 DOI: 10.1007/s00406-004-0531-0.

References

Crow T . Molecular pathology of schizophrenia: more than one disease process?. Br Med J. 1980; 280(6207):66-8. PMC: 1600263. DOI: 10.1136/bmj.280.6207.66. View

Lieberman J, Kane J, Gadaleta D, Brenner R, LESSER M, Kinon B . Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry. 1984; 141(5):633-8. DOI: 10.1176/ajp.141.5.633. View

Merali Z . Prolactin levels and amphetamine-induced behavioural changes following fluphenazine decanoate administration. Prog Neuropsychopharmacol. 1981; 5(5-6):603-7. DOI: 10.1016/0364-7722(81)90056-4. View

Angrist B, Rotrosen J, Gershon S . Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl). 1980; 72(1):17-9. DOI: 10.1007/BF00433802. View

Janowsky D, Davis J, Sekerke H . Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry. 1973; 28(2):185-91. DOI: 10.1001/archpsyc.1973.01750320023004. View

VAN KAMMEN D, Bunney Jr W, Docherty J, Marder S, EBERT M, Rosenblatt J . d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry. 1982; 139(8):991-7. DOI: 10.1176/ajp.139.8.991. View

Mattson R, CALVERLEY J . Dextroamphetamine-sulfate-induced dyskinesias. JAMA. 1968; 204(5):400-2. View

Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J . Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl). 1982; 78(2):128-30. DOI: 10.1007/BF00432248. View

Guttmann E, SARGANT W . Observations on Benzedrine. Br Med J. 2010; 1(3984):1013-5. PMC: 2088790. DOI: 10.1136/bmj.1.3984.1013. View

10.

Brown W, Laughren T . Low serum prolactin and early relapse following neuroleptic withdrawal. Am J Psychiatry. 1981; 138(2):237-9. DOI: 10.1176/ajp.138.2.237. View

11.

Wistedt B, Wiles D, KOLAKOWSKA T . Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet. 1981; 1(8230):1163. DOI: 10.1016/s0140-6736(81)92334-5. View

12.

DeLay J . Pharmacological explorations of the personality; narco-analysis and methedrine shock. Proc R Soc Med. 1949; 42(7):491-6. PMC: 2081122. View

13.

Langer G, SACHAR E, Halpern F, Gruen P, Solomon M . The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine studies in normal men. J Clin Endocrinol Metab. 1977; 45(5):996-1002. DOI: 10.1210/jcem-45-5-996. View

14.

HOPE J, CALLAWAY E, SANDS S . Intravenous pervitin and the psychopathology of schizophrenia. Dis Nerv Syst. 1951; 12(3):67-72. View

15.

VAN KAMMEN D, Docherty J, Bunney Jr W . Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry. 1982; 17(2):233-42. View